Creatine supplementation improves neural progenitor cell survival in Huntington's disease
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Preclinical and clinical studies suggest that striatal transplantation of neural stem cells (NSCs) and neural progenitor cells (NPCs) may be an appealing and valuable system for treating Huntington's disease. Nevertheless, for a neural replacement to become an effective translational treatment for Huntington's disease, a certain number of difficulties must be addressed, including how to improve the integration of transplanted cell grafts with the host tissue, to elevate the survival rates of transplanted cells, and to ensure their directed differentiation into specific neuronal phenotypes. Research focusing on the translational applications of creatine (Cr) supplementation in NSC and NPC cell replacement therapies continues to offer promising results, pointing to Cr as a factor with the potential to improve cell graft survivability and encourage differentiation toward GABAergic phenotypes in models of striatal transplantation. Here, we evaluate research examining the outcomes of Cr supplementation and how the timing of supplementation regimes may affect their efficacy. The recent studies indicate that Cr's effects vary according to the developmental stage of the cells being treated, noting the dynamic differences in creatine kinase expression over the developmental stages of differentiating NPCs. This research continues to move Cr supplementation closer to the widespread clinical application and suggests such techniques warrant further examination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondria, oxygen free radicals, disease and ageing
Raha, S., & Robinson, B. H. (2000) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)01674-1 · Cited by 1,066 · cited 5×
“[28-30] Because Cr can cross the blood–brain barrier and has a low toxicity profile, Cr supplementation is an increasingly appealing paradigm for supporting cell-based therapies to treat HD.[31,32] The safety of Cr supplementation suggests that it could be implemented both as a pretreatment for NSCs and NPCs before tr…”
BackgroundInfluentialMitochondrial defect in Huntington's disease caudate nucleus
Gu, M., Gash, M. T., Mann, V. M., Javoy‐Agid, F., Cooper, J. M., & Schapira, A. H. V. (1996) · Annals of Neurology · doi:10.1002/ana.410390317 · Cited by 758 · cited 3×
“[21] Prior investigations have revealed that neural degeneration in HD corresponds to a reduction in cellular energy metabolism in affected neurons, evidenced by a decrease in activity across mitochondrial complexes II and III.”
BackgroundNeuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease
Ferrante, R. J., Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Kuemmerle, S., Kubilus, J. K., Kaddurah-Daouk, R., Hersch, S. M., & Beal, M. F. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04389.2000 · Cited by 522
Human neural stem cells enhance structural plasticity and axonal transport in the ischaemic brain
Andres, R. H., Horie, N., Slikker, W., Keren-Gill, H., Zhan, K., Sun, G., Manley, N. C., Pereira, M. P., Sheikh, L. A., McMillan, E. L., et al. (2011) · Brain · doi:10.1093/brain/awr094 · Cited by 329
Self-citationCreatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG
Hersch, S. M., Gevorkian, S., Marder, K., Moskowitz, C., Feigin, A., Cox, M., Como, P., Zimmerman, C., Lin, M., Zhang, L., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000194318.74946.b6 · Cited by 313 · cited 1×
“[27] The clinical safety of Cr supplementation has been tested in three Phase II clinical trials carried out on symptomatic HD patients with results demonstrating this treatment bears no adverse effects.[28-30] Because Cr can cross the blood–brain barrier and has a low toxicity profile, Cr supplementation is an increa…”
BackgroundWallimann, T., Dolder, M., Schlattner, U., Eder, M., Hornemann, T., O'Gorman, E., Rück, A., & Brdiczka, D. (1998) · BioFactors · doi:10.1002/biof.5520080310 · Cited by 230 · cited 1×
“Cr is a nitrogenous amine which can be reversibly phosphorylated by the creatine kinase (CK) family of isozymes to form phosphocreatine (PCr).[19,20] Cr and PCr function together as a cellular energy shuttle, transferring inorganic phosphate to ATP-starved regions under high metabolic demand.”
BackgroundSelf-citationBrewer, G. J., & Wallimann, T. W. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741968.x · Cited by 230 · cited 1×
“[25] Neuroprotective effects of Cr have been reported in experimental models of HD and other neurodegenerative diseases previously.[47-58] Importantly, Andres et al.”
BackgroundSelf-citationDedeoglu, A., Kubilus, J. K., Yang, L., Ferrante, K. L., Hersch, S. M., Beal, M. F., & Ferrante, A. R. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01706.x · Cited by 169 · cited 1×
“[25] Neuroprotective effects of Cr have been reported in experimental models of HD and other neurodegenerative diseases previously.[47-58] Importantly, Andres et al.”
Background
Research works printed but not linked: 50
- Nayak, 2011, Huntington's disease: An immune perspective, Neurol Res Int, 563784
- Sanberg, 1984, Scientific approaches to Huntington's disease, CRC Crit Rev Clin Neurobiol, 1
- Hefter, 1987, Impairment of rapid movement in Huntington's disease, Brain, 585
- A, 1993, The Huntington's Disease Collaborative Research Group, Cell, 971
- Deckel, 1983, Reversal of long-term locomotor abnormalities in the kainic acid model of Huntington's disease by day 18 fetal striatal implants, Eur J Pharmacol, 287
- Dunnett, 1988, Striatal grafts in rats with unilateral neostriatal lesions – III.Recovery from dopamine-dependent motor asymmetry and deficits in skilled paw reaching, Neuroscience, 813
- Isacson, 1986, Graft-induced behavioral recovery in an animal model of Huntington disease, Proc Natl Acad Sci U S A, 2728
- McBride, 2004, Human neural stem cell transplants improve motor function in a rat model of Huntington's disease, J Comp Neurol, 211
- Roberts, 2006, Preservation of striatal tissue and behavioral function after neural stem cell transplantation in a rat model of Huntington's disease, Neuroscience, 1187
- Aubry, 2008, Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats, Proc Natl Acad Sci U S A, 16707
- Kordower, 1997, Grafts of EGF-responsive neural stem cells derived from GFAP-hNGF transgenic mice: Trophic and tropic effects in a rodent model of Huntington's disease, J Comp Neurol, 96
- Bachoud-Lévi, 2000, Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease, Exp Neurol, 194
- Bachoud-Lévi, 2000, Motor and cognitive improvements in patients with Huntington's disease after neural transplantation, Lancet, 1975
- Freeman, 2000, Transplanted fetal striatum in Huntington's disease: Phenotypic development and lack of pathology, Proc Natl Acad Sci U S A, 13877
- Hauser, 2002, Bilateral human fetal striatal transplantation in Huntington's disease, Neurology, 687
- Gallina, 2010, Human striatal neuroblasts develop and build a striatal-like structure into the brain of Huntington's disease patients after transplantation, Exp Neurol, 30
- Bachoud-Lévi, 2006, Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: A long-term follow-up study, Lancet Neurol, 303
- Reuter, 2008, Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease, J Neurol Neurosurg Psychiatry, 948
- Wallimann, 1998, Creatine kinase: An enzyme with a central role in cellular energy metabolism, MAGMA, 116
- Andres, 2008, Functions and effects of creatine in the central nervous system, Brain Res Bull, 329
- Calabresi, 2001, Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine, J Neurosci, 5110
- Aronin, 1995, CAG expansion affects the expression of mutant Huntingtin in the Huntington's disease brain, Neuron, 1193
- Andres, 2016, The effects of creatine supplementation on striatal neural progenitor cells depend on developmental stage, Amino Acids, 1913
- Andres, 2005, Effects of creatine treatment on survival and differentiation of GABA-ergic neurons in cultured striatal tissue, J Neurochem, 33
- Andres, 2010, Creatine improves the metabolic state of murine and human neural stem cells and improves expansion and neuronal induction, Regen Med, 2
- Verbessem, 2003, Creatine supplementation in Huntington's disease: A placebo-controlled pilot trial, Neurology, 925
- Rosas, 2014, PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease, Neurology, 850
- Ohtsuki, 2002, The blood-brain barrier creatine transporter is a major pathway for supplying creatine to the brain, J Cereb Blood Flow Metab, 1327
- Shao, 2006, Risk assessment for creatine monohydrate, Regul Toxicol Pharmacol, 242
- Slosman, 2001, Brain energy metabolism in Alzheimer's disease: 99mTc-HMPAO SPECT imaging during verbal fluency and role of astrocytes in the cellular mechanism of 99mTc-HMPAO retention, Brain Res Brain Res Rev, 230
- Schlattner, 2006, Mitochondrial creatine kinase in human health and disease, Biochim Biophys Acta, 164
- Aksenov, 2000, Oxidative modification of creatine kinase BB in Alzheimer's disease brain, J Neurochem, 2520
- Wallimann T, Tokarska-Schlattner M, Neumann D, Epand RM, Epand RF, Hornemann T, et. al. The phosphocreatine circuit: Molecular and cellular physiology of creatine kinases, sensitivity to free radicals, and enhancement by creatine supplementation. In: Saks V, editor. Molecular System Bioenergetics: Energy for Life. Weinheim: Wiley-VCH Verlag GmbH & Co.; 2007. p. 195-264. · DOI · Paper page
- Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The Genetic Basis of Human Cancer. New York: McGraw-Hill; 2002. p. 93-113.
- Schulze, 2003, Creatine deficiency syndromes, Mol Cell Biochem, 143
- Lin, 2013, Enhancement of brain-type creatine kinase activity ameliorates neuronal deficits in Huntington's disease, Biochim Biophys Acta, 742
- Bürklen, 2006, The creatine kinase/creatine connection to Alzheimer's disease: CK-inactivation, APP-CK complexes and focal creatine deposits, J Biomed Biotechnol, 35936
- Braissant, 2002, Ammonium-induced impairment of axonal growth is prevented through glial creatine, J Neurosci, 9810
- Ducray, 2007, Creatine promotes the GABAergic phenotype in human fetal spinal cord cultures, Brain Res, 50
- Bourdelas, 2009, Dynamic expression pattern of distinct genes in the presomitic and somitic mesoderm during Xenopus development, Int J Dev Biol, 1075
- Watts, 1997, Effect of embryonic donor age and dissection on the DARPP-32 content of cell suspensions used for intrastriatal transplantation, Exp Neurol, 271
- Watts, 2000, Embryonic donor age and dissection influences striatal graft development and functional integration in a rodent model of Huntington's disease, Exp Neurol, 85
- Matthews, 1998, Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease, J Neurosci, 156
- Shear, 2000, Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats, Neuroreport, 1833
- Andres, 2005, Effects of creatine treatment on the survival of dopaminergic neurons in cultured fetal ventral mesencephalic tissue, Neuroscience, 701
- Andres, 2005, Creatine supplementation improves dopaminergic cell survival and protects against MPP+ toxicity in an organotypic tissue culture system, Cell Transplant, 537
- Klivenyi, 1999, Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis, Nat Med, 347
- Klivenyi, 2004, Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis, J Neurochem, 576
- Dupuis, 2004, Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: Benefit of a high-energy diet in a transgenic mouse model, Proc Natl Acad Sci U S A, 11159
- Zhang, 2003, Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS, Ann Neurol, 267
Cited by
Antonio, J., Candow, D. G., Forbes, S. C., Gualano, B., Jagim, A. R., Kreider, R. B., Rawson, E. S., Smith-Ryan, A. E., VanDusseldorp, T. A., Willoughby, D. S., et al. (2021) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-021-00412-w · Cited by 345
Creatine monohydrate supplementation for older adults and clinical populations
Candow, D. G., Ostojic, S. M., Chilibeck, P. D., Longobardi, I., Gualano, B., Tarnopolsky, M. A., Wallimann, T., Moriarty, T., Kreider, R. B., Forbes, S. C., et al. (2025) · Journal of the International Society of Sports Nutrition · doi:10.1080/15502783.2025.2534130 · Cited by 43
Self-citationThanasupawat, T., Glogowska, A., Pascoe, C., Krishnan, S. N., Munir, M., Begum, F., Beiko, J., Krcek, J., Del Bigio, M. R., Pitz, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179566 · Cited by 8
“Our patient GBM cell models may be valuable new tools to address the role of endogenous CKM in GBM bioenergetics [70].”
Background
Metadata
- Authors
- Widmer, H., Andres, R., & Wallimann, T.
- Venue
- Brain Circulation
- Publisher
- Medknow
- Published
- 2016
- Volume
- 2
- Issue
- 3
- Pages
- 133
- ISSN
- 2394-8108 (ISSN-L)
- OpenAlex
- W2534060727
- Cited by
- 14
- References
- 8
- FWCI
- 0.29
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.